Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Drug Saf. 2017 Mar;40(3):263–272. doi: 10.1007/s40264-016-0490-1

Table 5.

Regression analyses of risk factors for multiple co-prescriptions of clopidogrel and omeprazole or esomeprazole by different providers, where each overlapping coverage was more than 14 days.

Risk factor Co-prescriptions of clopidogrel and omeprazole/esomeprazole Co-prescriptions of drugs interacting with antiepileptics, anticoagulants/antiplatelets, tricyclic antidepressants, immunosuppressants or HMG-CoA reductase inhibitors
OR (95% CI) p-value OR (95% CI) p-value
Age 1.11 (1.07 – 1.15) <0.0001 1.04 (1.02 – 1.06) <0.0001
Charlson index 1.20 (1.001 – 1.43)       0.049 1.19 (1.05 – 1.35)     0.005
Number of providers 1.13 (1. 80 – 1.19) <0.0001 1.13 (1.10 – 1.17) <0.0001
Presence of PCP 0.34 (0.13 – 0.88)     0.026 0.36 (0.17 – 0.75)     0.006
Care density 0.70 (0.50 – 0.97)     0.032 0.75 (0.62 – 0.92)     0.006